scPharmaceuticals Soars as FUROSCIX Sales Double and CKD Launch Gains Momentum

Key Highlights:

• Shares up 19% intraday following Q1 earnings beat
• FUROSCIX revenue grows 93% YoY; CKD launch sees early traction
• Autoinjector submission set for Q3 2025, fueling future upside

Shares of scPharmaceuticals Inc. (Nasdaq: SCPH) jumped over 19% on Wednesday, trading at $2.67 by late morning, after the company reported a robust set of first-quarter 2025 results and an encouraging business update highlighting commercial progress for its flagship therapy, FUROSCIX.

The Massachusetts-based biotech firm posted Q1 product revenue of $11.8 million, a striking 93% increase from $6.1 million a year ago, driven by strong uptake of FUROSCIX in both chronic heart failure and its newly approved chronic kidney disease (CKD) indication. The company formally launched FUROSCIX for CKD in April following an FDA nod in March.

Notably, the first quarter saw approximately 13,900 doses of FUROSCIX filled—a 73% YoY surge. Sales to Integrated Delivery Networks more than doubled from the prior quarter, reinforcing the commercial momentum behind the therapy.

CEO John Tucker expressed optimism, highlighting early nephrologist adoption and the impact of Medicare out-of-pocket smoothing, which boosted prescription volumes in Q2. “We are seeing an acceleration in our fill rate and units shipped,” Tucker said, signaling a positive revenue trajectory for the remainder of 2025.

Investors are also watching closely for the company’s upcoming sNDA submission for its FUROSCIX autoinjector (SCP-111), expected in Q3 2025. The device aims to dramatically reduce administration time from five hours to less than ten seconds—potentially a game-changer in home-based fluid management.

Despite rising revenue, net loss widened to $19.7 million from $14.1 million YoY, driven by increased R&D and SG&A spending, which management attributed to expansion efforts. Still, with $57.5 million in cash on hand and strong gross margins, the company remains in a solid financial position.

With shares still far below the $15.17 one-year analyst target, Wednesday’s rally may signal the beginning of renewed investor confidence—especially if FUROSCIX continues gaining traction in both existing and expanded markets.